Evidence map›Paper›PMID 33301434›Full record

ArticleMMWR. Morbidity and mortality weekly report2020

Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.

Margaret A Honein, Athalia Christie, Dale A Rose, John T Brooks, Dana Meaney-Delman, Amanda Cohn, Erin K Sauber-Schatz, Allison Walker, L Clifford McDonald, Leandris C Liburd and 10 more

Abstract read
In one paragraph

Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Evaluating the Impact of the COVID-19 Pandemic on Pediatric Asthma Incidence.The journal of allergy and clinical immunology. In practice · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Margaret A HoneinCDC COVID-19 Emergency Response.
Athalia ChristieCDC COVID-19 Emergency Response.
Dale A RoseCDC COVID-19 Emergency Response.
John T BrooksCDC COVID-19 Emergency Response.
Dana Meaney-DelmanCDC COVID-19 Emergency Response.
Amanda CohnCDC COVID-19 Emergency Response.
Erin K Sauber-SchatzCDC COVID-19 Emergency Response.
Allison WalkerCDC COVID-19 Emergency Response.
L Clifford McDonaldCDC COVID-19 Emergency Response.
Leandris C LiburdCDC COVID-19 Emergency Response.
Jeffrey E HallCDC COVID-19 Emergency Response.
Alicia M FryCDC COVID-19 Emergency Response.
Aron J HallCDC COVID-19 Emergency Response.
Neil GuptaCDC COVID-19 Emergency Response.
Wendi L KuhnertCDC COVID-19 Emergency Response.
Paula W YoonCDC COVID-19 Emergency Response.
Adi V GundlapalliCDC COVID-19 Emergency Response.
Michael J BeachCDC COVID-19 Emergency Response.
Henry T WalkeCDC COVID-19 Emergency Response.
CDC COVID-19 Response Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the 10 months since the first confirmed case of coronavirus disease 2019 (COVID-19) was reported in the United States on January 20, 2020 (1), approximately 13.8 million cases and 272,525 deaths have been reported in the United States. On October 30, the number of new cases reported in the United States in a single day exceeded 100,000 for the first time, and by December 2 had reached a daily high of 196,227.* With colder weather, more time spent indoors, the ongoing U.S. holiday season, and silent spread of disease, with approximately 50% of transmission from asymptomatic persons (2), the United States has entered a phase of high-level transmission where a multipronged approach to implementing all evidence-based public health strategies at both the individual and community levels is essential. This summary guidance highlights critical evidence-based CDC recommendations and sustainable strategies to reduce COVID-19 transmission. These strategies include 1) universal face mask use, 2) maintaining physical distance from other persons and limiting in-person contacts, 3) avoiding nonessential indoor spaces and crowded outdoor spaces, 4) increasing testing to rapidly identify and isolate infected persons, 5) promptly identifying, quarantining, and testing close contacts of persons with known COVID-19, 6) safeguarding persons most at risk for severe illness or death from infection with SARS-CoV-2, the virus that causes COVID-19, 7) protecting essential workers with provision of adequate personal protective equipment and safe work practices, 8) postponing travel, 9) increasing room air ventilation and enhancing hand hygiene and environmental disinfection, and 10) achieving widespread availability and high community coverage with effective COVID-19 vaccines. In combination, these strategies can reduce SARS-CoV-2 transmission, long-term sequelae or disability, and death, and mitigate the pandemic's economic impact. Consistent implementation of these strategies improves health equity, preserves health care capacity, maintains the function of essential businesses, and supports the availability of in-person instruction for kindergarten through grade 12 schools and preschool. Individual persons, households, and communities should take these actions now to reduce SARS-CoV-2 transmission from its current high level. These actions will provide a bridge to a future with wide availability and high community coverage of effective vaccines, when safe return to more everyday activities in a range of settings will be possible.

Indexed as

Guidelines as TopicPublic Health PracticeCommunity-Acquired InfectionsCOVID-19HumansUnited States

Identifiers

PMID33301434
PMCPMC7737690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.